Ms. Alison Silva, MA
President and Chief Executive Officer
Alison Silva is the President, Chief Executive Officer and a Director of Cotinga Pharmaceuticals Inc. Previously, she was a co‐founder, Executive Vice President and Chief Operating Officer at Synlogic, Inc. where she lead the regulatory strategy, drug development, and operational aspects of the company’s focus on the discovery and development of engineered therapeutic probiotics. Alison is also a co‐founder of The Orphan Group, a specialty consulting company focused on assisting companies with developing and implementing their orphan drug strategy and product lifecycle management.
Alison previously held the position of Chief Operating Officer at SLA Pharma, a GI‐oncology focused biotech company, where she was responsible for heading up U.S. corporate and clinical operations for their pipeline of orphan drug candidates. Prior to joining SLA Pharma, Alison was Vice President of Drug Development at Marina Biotech through its acquisition of Cequent Pharmaceuticals in 2010, where she held the same role since 2007. Alison began her career in drug development in clinical operations with various positions at Pfizer, Massachusetts General Hospital, and the University of Massachusetts. Alison holds a Bachelor’s degree from Clark University and a Master’s degree from Clark University and UMass Medical Center.
Dr. Richard Ho, M.D.-Ph.D.
Chief Scientific Officer
Dr. Richard Ho is the Chief Scientific Officer and leads Cotinga’s scientific programs from early stage discovery through preclinical and clinical development. Prior to joining Cotinga, Dr. Ho was Chair of the Scientific Advisory Board for Marina Biotech from 2014 to 2016, and was its Executive Vice President, Research and Development from 2011 to 2014. He served as Senior Medical Director at Entelos, Inc. from 2008 to 2011, where he oversaw academic and governmental collaborations including a Cooperative Research and Development Agreement with the FDA. From 2007 to 2008, Dr. Ho was a Principal at Rosa and Co. where he worked with pharmaceutical and biotechnology companies on physiological modeling efforts in several disease areas.
Dr. Ho began his industry career at Johnson & Johnson Pharmaceutical Research & Development starting as a fellow in Medical Informatics and advancing to the position of Director of Disease Modeling. While at Johnson & Johnson, he led a team that championed systems biology and personalized medicine approaches to understanding and treating human disease. In this position, he coordinated model-based analysis and research with global clinical and preclinical teams developing both small and large molecule compounds. Dr. Ho received his M.D.-Ph.D. from the University at Buffalo School of Medicine and received his A.B. in physics from Harvard College.
Mr. Gene Kelly
Chief Financial Officer
Mr. Gene Kelly is the Chief Financial Officer. He began his business career spending six years in public accounting with Clarkson Gordon. He brings to the company extensive experience from his 16-year career with the Cuddy Group of Companies, a large multinational multiplier turkey breeding company where he held various positions including: Director of Finance (Cuddy Farms), Vice President Commodity and Industry Affairs (Cuddy Foods), Vice President Strategic Implementations (Cuddy Farms) and Director of Quality.